Get the Weekly Intelligence Brief — top committee picks every Sunday.
TFX · NYSE · STOCK

Teleflex (TFX) Stock Analysis

Healthcare Updated October 10, 2026
$125.10
52W $100.18 – $145.00
56/100
$5.54B
-5.4
0.83
AI Committee Verdict
Watch
56/100
Conviction: Moderate · 60% agreement · 5 analysts
+6.4%
-3.1%
2.07:1
Moderate

Is TFX Bullish or Bearish?

Mixed. Innellis AI committee rates Teleflex Incorporated (TFX) Watch with a composite score of 56/100 , based on 5 analysts with 60% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +4.03 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -15.97 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • News sentiment is positive (+0.20 across 25 articles, 14d) — News
Bear Case
  • ROE of only -31.9% -- cheap may mean cheap for a reason — Value
  • Revenue declining -14.5% YoY -- this is not a growth story right now — Growth
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
56/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 60%
of 192 Healthcare peers
Value Analyst neutral
42 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -31.9% -- cheap may mean cheap for a reason
Growth Analyst neutral
50 / 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− Revenue declining -14.5% YoY -- this is not a growth story right now
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
64 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 25 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 56.0 to 56.0.

Analyst-level changes:
  • News Analyst: +1 bullish signal(s).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
47.6
Neutral
MACD Histogram
0.364
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Lh Ll
Support
$121.22
Resistance
$133.13
Bollinger %B
0.49
Inside Bands
Price vs Moving Averages
EMA 9
$124.89 Above
EMA 21
$126.62 Below
EMA 50
$129.56 Below
EMA 200
$127.98 Below

Fundamental Analysis

Valuation
98
Growth
66
Profitability
21
Financial Health
88
Cash Flow
70
Valuation
P/E Ratio -5.4×
P/B Ratio 1.88×
PEG Ratio -0.28
Dividend Yield 1.09%
52W High $145.00
52W Low $100.18
Quality & Growth
ROE -2898.3%
ROA -1303.6%
Gross Margin 5376.5%
Operating Margin 334.9%
Revenue Growth YoY —
Debt / Equity 0.99
AI Fundamental Assessment
P/E ratio of -5.4 (inexpensive relative to a 15-40x range); Price-to-book of 1.9x; PEG ratio of -0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -29.0%; Return on assets of -13.0%; Net margin of -39.6%; Gross margin of 53.8%; Current ratio of 2.60 (healthy short-term liquidity); Debt-to-equity of 0.99; Free cash flow per share is positive (8.97); Most recent quarter beat estimates by 36.0%; 2 consecutive earnings beats; EPS growth accelerating (-28.0% -> +26.6% QoQ); Analyst estimates falling over recent quarters
Get the Full TFX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime